Posts

The Future of Gene Therapies: Three Trends

“Maps don’t show you where you will go in life, they show you where you might go...

FDA approves Abbott’s latest lab blood test for concussion

The Food and Drug Administration (FDA) has cleared Abbott’s laboratory blood tes...

Servier’s acquisition of Agios’ INDIGO trial bears posi...

French drugmaker Servier recently acquired Agios Pharmaceutical’s cancer unit fo...

FDA Advisory Committee Recommends Agency Approve Two RS...

Two RSV vaccinations targeted toward elders, one from Pfizer and one from GSK, h...

US FDA approves Novartis’ Tafinlar and Mekinist combina...

The approval of the combination of Tafinlar and Mekinist is based on the Phase I...

UCB enters drug discovery collaboration with Aitia

The collaboration will combine the use of new drug targets for the disease from ...

Talem and Libera Bio partner for discovery of AI-driven...

The collaboration will use the LENSai Full Suite of Integrated Intelligence Tech...

Which biotechs need to find a new bank after the collap...

One immediate outcome of Silicon Valley Bank’s collapse will be its former clien...

Legal challenges put off label use of gender affirming ...

Experts debunk gender-affirming care safety concerns and detail logistical barri...

UK MHRA grants marketing authorisation for argenx’s gMG...

Vyvgart’s approval is based on the data obtained from the global Phase III ADAPT...

Tapping into digital therapeutics to improve neurologic...

Despite advancing research, clinical data and timely reimbursement are crucial f...

Risk sharing agreements soar as market access risk incr...

GlobalData analysts detail a rise in risk sharing agreements with pharma compani...

LCRF, Daiichi Sankyo and AstraZeneca enter research col...

The partnership is intended to request proposals for research grants focused on ...

Pharmanovia signs licence deal for Aeterna Zentaris’ Gh...

Ghryvelin is used for the diagnosis of Adult Growth Hormone Deficiency.

‘I’m terrified’: Patients scramble for treatment after ...

The abrupt closure of Ketamine Wellness Centers is one of the bigger upheavals i...

STAT+: Moderna CEO made $398 million in 2022, but still...

Moderna CEO Stéphane Bancel made $398 million in 2022. Most of that, according t...